Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMTX 705

Next Previous
Drug Profile

OMTX 705

Alternative Names: Anti-FAPα:Cytolysin ADC; OMTX-705

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncomatryx
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma
  • Phase I Solid tumours

Most Recent Events

  • 24 Jul 2025 Phase-I/II clinical trials in Adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (IV) (CTIS2025-520743-33-00)
  • 30 May 2025 Efficacy, adverse events and pharmacokinetics data from the phase I trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 06 May 2025 Phase-I clinical trials in Adenocarcinoma (Metastatic disease, Late-stage disease) in USA and Spain (Parenteral) prior to May 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top